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Abstract
Objective The goal of this paper is to discuss cancer-
related fatigue (CRF) and address issues related to the
investigation into potential biological and genetic causal
mechanisms. The objectives are to: (1) describe CRF as a
component of quality of life (QOL); (2) address measure-
ment issues that have slowed progress toward an under-
standing of mechanisms underlying this symptom; (3)
review biological pathways and genetic approaches that
have promise for the exploration of causal mechanisms of
CRF; and (4) offer directions for future research.
Methods Review, synthesis, and interpretation of the
literature.
Results Until recently, CRF and QOL have been under-
stood primarily as subjective patient-reported experiences.
With increased understanding of human genetics, theories
and research are being expanded to incorporate biological
and genetic understandings of these subjective experiences.
Proposed biological and genetic mechanisms of CRF that
have been examined include cytokine dysregulation,
hypothalamic–pituitary–adrenal (HPA) axis dysfunction,
five hydroxy tryptophan (5-HT) neurotransmitter dysregu-
lation, circadian rhythm disruption, alterations in adenosine
triphosphate (ATP) and muscle metabolism, and vagal
afferent activation. Approaches to the study of genetic
mechanisms have also been addressed including candidate
genes, genome-wide scanning, and gene expression. Based
on the review and synthesis of the literature, directions for
future research are proposed.
Conclusions Understanding the biological and genetic
basis of CRF has the potential to contribute to a more com-
plete understanding of the genetic determinants of QOL.
Keywords Cancer-related fatigue  Patient-reported
outcomes  Biological mechanisms  Genetic variables 
Quality of life
Introduction
The goal of this paper is to discuss fatigue as a component of
quality of life (QOL) and address issues related to the
investigation into potential biological and genetic causal
mechanisms. There is a large body of research on fatigue that
has focused on it as a cancer-related symptom, so this dis-
cussion will address fatigue in the context of cancer. First, we
will describe cancer-related fatigue (CRF) as a component of
QOL. Next, we will address measurement issues that have
slowed progress toward an understanding of mechanisms
underlying this highly prevalent symptom. This will be
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followed by a review of biological pathways that have
promise for the exploration of causal mechanisms. Finally,
we will offer directions for future research. Elucidating the
genetic basis for CRF has the potential to contribute to a more
complete understanding of the genetic basis of QOL.
We are on the brink of a new understanding of sub-
jective experiences such as CRF and QOL. To date, these
constructs have been understood largely as subjective
patient-reported experiences. This limited view is probably
due in part to outdated notions of the mind–body dichot-
omy in which subjective experiences are relegated to the
domain of the mind as separate from the body or biological
domain. As our understanding of genetics has grown, it has
become clear that genetic mechanisms are involved in a
broad range of human functions including subjective
experiences such as symptoms and QOL. Clearly, our
theories and research must be expanded to incorporate
biological as well as psychological and behavioral deter-
minants of subjective experience. This paper will highlight
some of the issues that need to be addressed in this tran-
sition using the specific example of CRF.
Fatigue and quality of life
Cancer-related fatigue (CRF) is a highly prevalent symp-
tom. The incidence ranges from 25 to 99% of patients
depending on the means of assessment and which patients
are assessed [1]. Fatigue is not confined to the active phase
of cancer. It has been identified as prevalent in survivors
with 17–30% reporting fatigue [2, 3]. Fatigue has been
identified as a multidimensional construct including phys-
ical and mental fatigue, activity reduction, and motivation
reduction [4]. Fatigue has also been coupled with decre-
ments in physical, psychological, and social functioning
that are also important domains of QOL. The high inci-
dence of fatigue is coupled with distress; patients have
reported fatigue to be the most distressing symptom they
have experienced [5, 6], even more so than pain [7].
The link between CRF and health-related quality of life
has been described both conceptually and empirically. The
adapted model of Wilson and Cleary [8] that provides the
conceptual framework for this series of papers proposes
that symptoms and the resultant functional decrements
impact overall quality of life [9]. As a highly prevalent
symptom resulting in significant functional deficits, CRF
can diminish QOL profoundly. The proposed associations
between CRF and QOL have been demonstrated empiri-
cally. A study of breast cancer patients showed that those
who reported clinically significant CRF (cases) at the
conclusion of treatment had worse physical and social
functioning and greater mood disturbance than those who
did not report CRF (non-cases) [10]. Another study of
breast cancer survivors showed that there were large dif-
ferences between fatigue cases and non-cases in all
domains of QOL except subjective perception of cognitive
disturbance [11]. Women with clinically significant CRF
had worse physical, emotional, and social functioning as
well as worse global health status than those without CRF.
This study also showed that fatigued survivors had poorer
body image and sexual functioning and greater mood dis-
turbance than those without CRF. These examples of CRF
and QOL are part of a large body of research, showing that
fatigue is strongly linked with health-related quality of life.
Measurement issues
Until recently, a consistent definition of CRF has been
lacking, but consensus is building through the work of
various consortia and working groups including the
National Comprehensive Cancer Network Fatigue Guide-
lines Committee [12] of what constitutes CRF. Recently,
an independent working group, Assessing the Symptoms of
Cancer using Patient-Reported Outcomes (ASCPRO),
developed a consensus definition of CRF as the perception
of unusual tiredness that varies in pattern of severity and
has a negative impact on ability to function in people who
have or have had cancer [13]. This definition represents the
consensus of clinical, academic, and pharmaceutical
investigators as well as cancer survivors.
While there is greater agreement about the conceptual
definition of CRF, work is still needed to clarify the
operational or case definition (See Appendix, Glossary).
Most subjective measures of CRF examine the dimensions
of severity and impact on functioning [13]. However, some
measures include additional dimensions including cogni-
tive [14–18] or emotional fatigue [15, 16, 18–20], energy
level [21, 22], or motivation [17]. These variations in
measured dimensions of CRF denote a lack of well-defined
criteria for distinguishing clinically important cases of CRF
from non-cases. Although some work has been done to
clarify the case definition of CRF [2, 10, 23, 24], more
work is needed. In order for the exploration of molecular
and genetic mechanisms of CRF to proceed, a well-defined
case definition is essential. Also, for simplicity and feasi-
bility of measurement, subjective measures of CRF need to
demonstrate congruence with the case definition.
Pathophysiologic pathways
Interest in the underlying biological pathways and genetic
mechanisms of fatigue is mounting. A pioneering study by
Alexander and colleagues [11] examined the differences
between CRF cases and non-cases with regard to biological
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and behavioral markers associated with different potential
mechanisms of CRF: anemia, inflammatory processes,
disruption of the HPA axis, metabolic disturbances, and
physical de-conditioning. Thirty percent of breast cancer
survivors met CRF criteria. With regard to mechanisms,
there were subtle immune and inflammatory disturbances
but no differences in indicators of other mechanisms.
The findings above suggest that inquiry into patho-
physiologic pathways and genetic mechanisms hold
promise for the identification of causal mechanisms and
potential treatment targets. The next section will review
current knowledge of pathways that have been associated
with the development and persistence of cancer-related
fatigue as well as current evidence for the genetic control
of cancer-related fatigue. The search strategy consisted of a
Medline search to identify articles on the etiology, genet-
ics, and physiopathology of CRF. The articles identified
were supplemented by articles previously identified by the
authors.
The pathophysiologic mechanisms involved in cancer-
related fatigue are not completely understood [25]. Dys-
regulation of several systems, both biochemical and
physiological, are likely involved in CRF and include both
peripheral and central mechanisms [26]. Peripheral fatigue
originates in the muscles and related tissues, whereas
central fatigue develops in the central nervous system and
results in progressive failure to transmit motor neuron
impulses. Proposed mechanisms of CRF include cytokine
dysregulation, hypothalamic–pituitary–adrenal (HPA) axis
dysfunction, five hydroxy tryptophan (5-HT) neurotrans-
mitter dysregulation, circadian rhythm disruption, altera-
tions in adenosine triphosphate (ATP) and muscle
metabolism, and vagal afferent activation [26, 27].
Cytokine dysregulation
Proinflammatory cytokines such as interleukin (IL)-1b, IL-
6, and tumor necrosis factor (TNF)-a have been evaluated
as markers of cancer-related fatigue [28, 29]. Breast cancer
survivors with persistent fatigue 2 or more years after
treatment had elevated levels of immune markers associ-
ated with proinflammatory cytokine activity [28]. Other
changes in immunity have included lower levels of natural
killer cells and natural killer cell activity associated with
higher levels of CRF [30–32].
Cancer and its treatment have been associated with
increases in plasma cytokines [26]. The mechanisms,
however, are not fully understood. Research has demon-
strated that the tumor micro-environment contains pro-
inflammatory cytokines such as IL-1, IL-6, and TNF-a
[33]. For various cancer diagnoses, elevated levels of cir-
culating cytokines and their receptors (most commonly
IL-6) have been observed at initial diagnosis and after
diagnosis of metastasis. These cytokines can contribute to
anemia, cachexia, anorexia, fever, infection, and depres-
sion, all of which can contribute to fatigue [34]. In addition
to acting as a growth factor for the neoplasm, specific
cytokines may contribute to fatigue through more specific
pathways. IL-1 and IL-6 and TNF-a have been shown to
suppress erythropoiesis, resulting in anemia [34]; TNF has
been associated with alterations in central nervous system
neurotransmission [26]; and interleukins, tumor necrosis
factor, interferon-c, and leukemia inhibitory factor can act
as chachectins [34, 35]. Cachexia can result in tissue
wasting and resulting fatigue, and interferon can produce
neurasthenia, a neurological fatigue [36]. Cytokines,
especially IL-6, have also been associated with depression,
with fatigue as a manifestation [37, 38].
Schubert and colleagues examined the link between
CRF and specific inflammatory markers [39]. Conclusions
of this review were limited by the small number of studies,
small sample sizes, heterogeneity of study populations, and
inconsistency in selection of inflammatory markers for
study. However, general analyses based on weighting of
sample size demonstrated a significant positive correlation
between fatigue and levels of circulating inflammatory
markers. Specific markers that were associated with fatigue
included IL6, IL-1ra, and neopterin. Although IL-1b or
TNF-a have been proposed as markers in the fatigue
pathway, neither correlated with fatigue in several studies
of cancer-related fatigue [40–42]. The findings to date
provide initial support for further exploration of the
inflammatory pathway in the etiology of fatigue.
Hypothalamic–pituitary–adrenal axis dysfunction
The hypothalamic–pituitary–adrenal (HPA) axis controls
the release of cortisol in response to physical or psycho-
social stress [26]. Specifically, corticotropin-releasing
hormone (CRH) is secreted from the paraventricular
nucleus of the hypothalamus and acts with vasopressin to
release adrenocorticotropic hormone (ACTH) from the
anterior pituitary. ACTH stimulates the release of cortisol
from the adrenal cortex. The HPA axis also influences the
development of immune cells and cytokine production.
Low levels of cortisol are associated with fatigue and may
result from the direct suppression of the HPA axis by
cancer treatment or changes in 5-HT that result in
decreased stimulation of 5-HT1A receptors that signals the
release of CRH [43].
In healthy people, there is a diurnal pattern of cortisol
production with peak levels prior to awakening and a
steady decline throughout the day [44]. Breast cancer
survivors with persistent fatigue (in comparison with non-
fatigued survivors) had a flatter cortisol slope and signifi-
cant cortisol elevation in the late evening [45]. These
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results suggest that alterations in HPA axis activity could
influence fatigue.
Dysregulation of serotonin
Another hypothesis is that increased levels of 5-HT
(serotonin) in the brain and/or upregulation of 5-HT
receptors due to cancer or cancer treatment could result in
fatigue [26]. A suggested mechanism for this increased
fatigue is that activity of proinflammatory cytokines
including interleukin, interferon, IFN-c, and TNF-a may
stimulate indoleamine 2,3-dioxygenase to alter 5-HT
metabolism. Increases in 5-HT levels or upregulation of
5-HT receptors signals the release of CRH, in turn modi-
fying the HPA axis function to reduce somatomotor drive
and produce a sensation of decreased physical ability. In
animal studies, 5-HT levels were shown to increase during
sustained exercise; fatigue was observed at the highest
concentration of 5-HT [46]. Research in humans on exer-
cise-induced fatigue and chronic fatigue syndrome suggests
that 5-HT dysregulation may be implicated in the etiology
of fatigue [47].
The observed occurrence of fatigue and depression
together has led to a proposed common pathophysiological
mechanism involving 5-HT regulation in cancer patients
[48]. Two related clinical trials examined this hypothesis.
The first trial randomized 479 fatigued patients receiving
chemotherapy for any cancer diagnosis to receive paroxe-
tine hydrochloride (Paxil), a selective serotonin reuptake
inhibitor, 20 mg or placebo for 8 weeks [49]. The second
trial conceptually replicated the first trial in 94 breast
cancer patients [48]. Neither trial showed benefit in
reducing fatigue; however, both trials demonstrated a sig-
nificant effect of the drug on depressed mood. The results
do not support the hypothesis that central serotonin regu-
lation is a primary mechanism of cancer-related fatigue
during chemotherapy.
Circadian rhythm disruption
Circadian rhythms could play a significant role in the eti-
ology of fatigue through the modulation of arousal and
sleep [42]. The central circadian system and downstream
network of relay stations in the hypothalamus regulates
arousal and sleep. This system is most significantly affec-
ted by the input of light that creates neurophysiological
changes in the hypothalamus and melatonin that affects the
darkness period, neurons in the suprachiasmatic nuclei
(SCN) that regulate 24-h sleep patterns, and by afferent
nerve fibers groups that relay signals from the SCN to the
hypothalamus. Signals from the hypothalamus affect the
parasympathetic and sympathetic autonomic centers in the
brainstem and in turn affect the secretion of stress and
physiology regulating hormones. Circadian rhythm may
also be affected through SCN downstream signal disruption
that may occur in the dorsal or ventral nuclei or from input
from the brain’s visceral, limbic, and cortical systems.
Alterations in any part of the circadian system can
result in disruption of arousal and sleep patterns. SCN
ablation in animals has resulted in the permanent loss of
rhythmic rest, activity, and sleep behaviors. Research has
shown that fatigue in cancer patients undergoing treat-
ment was inversely related to activity during the day and
restless sleep at night [50, 51]. SCN peptides and ligands
of epidermal growth factor (EGF) receptor, released by
the cancer or in response to the stress of the cancer,
have been shown to reversibly inhibit activity and
deregulate 24-h sleep patterns [42]. Specific peptides
include EGF, TGF-a, and neuregulin-1, prokineticine-2,
and cardiotrophin-like cytokine. Individuals with damp-
ened or inconsistent circadian rhythms had higher levels
of fatigue than those with consistent rhythms [26]. Cir-
cadian rhythms have been affected significantly in
advanced stage or metastatic disease. Little or no effect
is noted with early-stage cancers. Specific mediators of
circadian rhythms, including cortisol levels and melato-
nin, have been shown to change in patients with cancer
[42].
Alterations in adenosine triphosphate
Dysregulation of ATP, the muscle’s major source of
energy, can result in peripheral fatigue. It is hypothesized
that cancer or its treatment, anorexia, or cachexia can lead
to defects in the ability to regenerate ATP in skeletal
muscles. This may be through the mechanism of altered
muscle protein metabolism [26]. Research investigating
chronic fatigue syndrome has demonstrated defects in ATP
synthesis and metabolism. Evidence of ATP dysregulation
in cancer patients is limited. However, a randomized
clinical trial of ATP infusions for advanced lung cancer
patients resulted in improved muscle strength and reduced
fatigue [52].
Vagal afferent nerve activation
Cancer or its treatment may cause release of peripheral
neuroactive agents that activate vagal afferent fibers with
suppression of somatic muscle activity and induction of
‘‘sickness behavior’’ in animals [26]. Based on the existing
data, it has been proposed that reflex inhibition of skeletal
muscle activity due to proinflammatory cytokines or 5-HT
could be responsible for cancer-related fatigue [33, 53].
There is little evidence to support this hypothesis although
the results of a few animal studies provide some support for
this mechanism [26].
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Summary
The discussion of multiple pathophysiological pathways
suggests that CRF is multidimensional [5–7]. While we do
not thoroughly understand all of the pathways, a number of
them have been identified as playing a role in CRF [25]. It
is possible that different pathophysiological mechanisms
are responsible for different dimensions of fatigue. For
instance, the existence of peripheral fatigue may be a result
of ATP dysregulation while circadian rhythm may con-
tribute mainly to mental fatigue. More generalized forms of
fatigue could involve central mechanisms such as cytokine
dysregulation. As fatigue severity increases, it is possible
that more pathways will be involved. Further delineation of
the aspects of fatigue associated with each of these path-
ways will assist in the identification of new intervention
targets more specifically aimed at the type of fatigue
experienced.
Genetics and fatigue
Advances in molecular and genetic technology now enable
the use of different methods for identifying the genes that
control the development and persistence of cancer-related
fatigue. Genome-wide scanning can be done without a
specific hypothesis or proposed pathway because thousands
of single nucleotide polymorphisms (SNP) can be exam-
ined simultaneously. Cancer-related symptoms are likely to
be influenced by the cumulative effect of several gene
polymorphisms [54]. Also cytokine genes are pleiotropic in
that the activity of one gene can have more than one effect
[55]. Also, genes that control other cancer-related symp-
toms (such as depression or pain) could influence fatigue
[54–56]. Genome-wide scanning would be useful in iden-
tifying combinations of genes that control fatigue.
Another type of association study is hypothesis driven
with candidate genes examined in specific pathways. The
pathway-based approach requires prior knowledge of
pathophysiologic processes and the formulation of specific
hypotheses about gene SNP that are likely to regulate the
development of specific symptoms such as fatigue. The
hypothesis-driven candidate gene approach can be used to
provide evidence in support of specific hypotheses about
the mechanisms of cancer-related fatigue.
Collado-Hidalgo used the candidate gene approach to
test whether variation in fatigue was influenced by gene
polymorphisms in the regulatory regions (promoters) of the
genes that encode proinflammatory cytokines [57]. SNP in
the promoter region of IL-1b (-511) and IL-6 (-174) have
been shown to control gene expression of cytokines asso-
ciated with breast cancer susceptibility and prognosis.
These candidate genes were evaluated as risk factors for
fatigue. IL-1b -511 and IL-6 -174 were each indepen-
dently associated with post-treatment fatigue in breast
cancer survivors. There was an overrepresentation of the
IL-1 CC allele and an underrepresentation of the TT allele
among survivors with persistent fatigue. There was also an
increased occurrence of homozygosity for the C allele
variant and the wild-type G allele for the IL-6 -174 (G/C)
polymorphism in fatigued survivors. The results suggest
that increased production of proinflammatory cytokines are
involved in the development of CRF.
Several cytokine genes and their polymorphisms have
been proposed as candidate markers for the study of CRF
[54].
• IL-1B—511 (C/T): As noted previously, there was
overrepresentation of the CC alleles and underrepresen-
tation of TT alleles among fatigued survivors [54, 57].
• IL-6—174 (G/C): It was previously noted that homo-
zygosity for both the variant C allele and the wild-type
G allele of the IL-6—174 (G/C) polymorphism was
overrepresented in the fatigued group [40–42, 54, 57].
• TNF-a—308 (G/A): This polymorphism has been
proposed for involvement in neoplastic cachexia which
is characterized, in part, by fatigue [54]. However, none
of the studies that examined the association between
TNF-a and fatigue demonstrated an association [30,
58].
• IL8—251 (T/A): Variation in the promoter SNP IL8—
251 (T/A) was found to affect risk for pain severity in
newly diagnosed untreated lung cancer patients by
influencing concentrations of IL8 [54, 55]. The asso-
ciation of this gene with fatigue is unknown.
• IL2—330 (T/G): This genetic polymorphism is
believed to regulate IL-2 production which has been
implicated in complex regional pain syndrome and
painful neuropathy [54]. Its association with CRF is
unknown.
An alternative to analyzing DNA using SNP is exam-
ining the transcript of genes, RNA. RNA synthesis is the
process by which DNA nucleotide sequence information is
transcribed into RNA nucleotide sequence information. If
the DNA codes for a protein, transcription is the first step
that leads to the expression of a gene. This is done by the
production of mRNA, a ‘‘chemical blueprint’’ for a protein
product. While genetic variation in DNA is constant
throughout life, RNA changes over time and is found to be
tissue specific; not all genes are similarly expressed in all
tissue.
Among the studies that have addressed global gene
expression and fatigue, a common problem is the lack of
statistical precision. The data sets are small, and measures
to correct for multiple testing have not been performed, or
at least not described. Generally, methods have not been
Qual Life Res (2010) 19:1419–1427 1423
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described in detail making inferences of the findings dif-
ficult. One could also argue that gene expression in blood
cells is not the optimal (but probably easiest accessible)
biomarker of fatigue.
Global gene expression has been used in a few studies of
non-cancer fatigue. Although this work has not been done
specifically in CRF, the findings of a non-cancer-related
fatigue syndrome could provide clues about gene expres-
sion profiles that would be applicable to CRF. In most
cases, gene expression of blood lymphocytes has been
used. Whistler and colleagues found 839 genes to be
associated with fatigue when contrasting 40 patients with
chronic fatigue and 37 healthy controls [59]. The genes
regulated oxidative phosphorylation, glucogenesis, lipid
metabolism, and several signal transduction pathways.
Given the fact that 19,000 probes were analyzed, the
problem of multiple tests was substantial. Later, the same
group adopted a different approach by using candidate
genes [60]. Gene sets for T- and B-cell regulation were
constructed, and expression was contrasted between cases
with fatigue and healthy controls. The results pointed at a
B-cell dysfunction in the blood array profiles.
Kerr adopted a two-stage approach first identifying 182
genes related to fatigue when examining the global gene
expression of lymphocytes in 25 cases with chronic fatigue
syndrome and myalgic encephalomyelitis and 50 controls
[61]. These genes were validated in 55 cases and 75 con-
trols and also demonstrated an association with immune
response, cancer, and cell death.
A study available through the CDC (public health
genomics office) evaluated 227 individuals from Wichita
with chronic fatigue syndrome [62]. SNPs in HPA axis–
associated genes, in neuroendocrine effector and receptor
genes, and in genes in the serotonergic system were found
to be related to fatigue.
Implications for future research
The preceding discussion was intended to broaden our
understanding of mechanisms that could be responsible to
the development and persistence of CRF. The next section
will suggest directions for future research.
Multiple clinical trials are currently underway to deter-
mine the efficacy of interventions to prevent and/or treat
CRF [13]. As the science continues to progress toward
individualized medicine, understanding the genetic dimen-
sions of CRF will become increasingly important in the
design of specific interventions to prevent and combat CRF.
Several avenues of research are recommended. First,
work is needed to further delineate the case definition of
CRF. This includes determining whether there are CRF
sub-types such as CRF with or without clinical depression.
Also more work is needed to examine the similarities and
dissimilarities of CRF and other chronic fatigue syn-
dromes. Such comparisons would further our understand-
ing of the mechanisms behind different fatigue syndromes.
This work is critical in developing a clear and specific of
CRF phenotype as a basis for studying CRF genotypes.
Related to the case definition of CRF is the need for further
research linking patient-reported measures of CRF to the
case definition.
A second area requiring further investigation is the
biological and genetic mechanisms of CRF to supplement
our more robust understanding of the subjective experi-
ence. Biological markers of CRF need to be identified, so
these can be tracked as part of the natural history of this
symptom along with subjective reports of CRF severity and
impact. Future research must elucidate the relationship of
these biological markers and currently known or postulated
pathophysiologic pathways involved in CRF with emerging
understanding of genetics, genes, and their expression in
CRF. As medical science continues to progress toward
individualized medicine, understanding the genetic
dimensions of CRF will become increasingly important in
the design of specific interventions to prevent and combat
CRF.
Summary
This paper has examined issues that need to be addressed to
increase our understanding of CRF as a component of QOL as
well as current evidence for biological pathways and genetic
mechanisms that could regulate the development and persis-
tence of cancer-related fatigue. Further research is needed to
expand our understanding of the biology and genetics of
fatigue in order to identify persons at risk for this debilitating
symptom as well as targets for intervention to alleviate it.
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Appendix: Glossary [63, 64]
Case Definition: Criteria or standards used to identify an
instance of a disease, syndrome, or condition;
DNA (deoxyribonucleic acid): The two-stranded mole-
cule that encodes genetic information;
Gene: The basic unit of inheritance. A sequence of DNA
bases that codes for a particular product;
Genome: All the DNA sequences of an organism;
Genotype: The genetic constitution of an organism that
is not manifested as outward characteristics;
Phenotype: Physical characteristics of an organism or
the presence of a disease that may or may not be genetic;
Polymorphism: A locus with two or more alleles
(alternative forms of a gene at a locus);
Functional polymorphism: DNA sequence variations
that alter the expression and/or functioning of the gene
product;
Single nucleotide polymorphism (SNP): Sequences in the
genome that differ by a single nucleotide between one
portion of the population and another.
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